Current Report Filing (8-k)
20 April 2020 - 2:43PM
Edgar (US Regulatory)
0001739104
false
0001739104
2020-04-19
2020-04-20
0001739104
us-gaap:CommonStockMember
2020-04-19
2020-04-20
0001739104
elan:TangiblePercentEquityUnitsMember
2020-04-19
2020-04-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): April 20, 2020
Elanco
Animal Health Incorporated
(Exact name of registrant as specified
in its charter)
Indiana
|
|
001-38661
|
|
82-5497352
|
(State
or other jurisdiction of
incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
2500 Innovation Way
Greenfield, Indiana
(Address
of principal executive offices)
|
|
46140
(Zip
Code)
|
Registrant’s telephone number, including
area code: (877) 352-6261
Not Applicable
(Former Name or Address, if Changed Since
Last Report)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name
of each exchange on which registered
|
Common Stock, no par value
|
ELAN
|
New York Stock Exchange
|
5.00% Tangible Equity Units
|
ELAT
|
New York Stock Exchange
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
On April 20, 2020, Elanco Animal Health Incorporated issued
a press release announcing the expansion of its existing leadership team to add a Chief Marketing Officer and three commercial
leaders to its current leadership team. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Elanco Animal Health Incorporated
|
|
|
|
Date: April 20, 2020
|
By:
|
/s/ Michael-Bryant Hicks
|
|
|
Name: Michael-Bryant Hicks
|
|
|
Title: Executive Vice President, General Counsel and Corporate Secretary
|
Elanco Animal Health (NYSE:ELAT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Elanco Animal Health (NYSE:ELAT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
Echtzeit-Nachrichten über Elanco Animal Health Incorporated (New York Börse): 0 Nachrichtenartikel
Weitere Elanco Animal Health Inc News-Artikel